U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07828327) titled 'Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma' on Sept. 14.
Brief Summary: An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
Study Start Date: Nov. 01
Study Type: INTERVENTIONAL
Condition:
Allergic Bronchopulmonary Aspergillosis
ABPA
Severe Eosinophilic Asthma
Intervention:
DRUG: Depemokimab
100 mg (1mL) Subcutaneous Solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qianfoshan Hospital
Information provided by (Responsible Party): Qian Qi,...